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Newborn screening for congenital
hypothyroidism: improvement in short‑term
follow‑up by audit and monitoring
Hafsa Majid1* , Sibtain Ahmed1, Imran Siddiqui1, Khadija Humayun2, Hussain Karimi3 and Aysha Habib Khan1

Abstract
Objective: Newborn screening for congenital hypothyroidism (CH) at our hospital during this study was by measurement of thyroid stimulating hormone (TSH) in serum samples. This audit was conducted over a 2 year period, to
determine the compliance of reporting of results greater than the screening cutoffs for serum TSH. Gaps of non-compliance were identified, and re-audit was undertaken after the corrective actions were taken.
Results: The critical limit was defined as serum TSH (≥ 20 µIU/ml) following consultation with a pediatric endocrinologist. All results above this limit were reported urgently to physicians. During the audit period, 27,407 tests were
performed, 0.7% had a value of ≥ 20 µIU/ml, of those only 62% were reported to the general paediatrician or neonatologist. Reasons for not reporting results included non-availability of contact information, lack of policy awareness by
technologists, critical results not highlighted on the computer display, and absence of regular monitoring. Corrective
measures were taken, and re-audit was done. During the re-audit period, a total of 22,985 tests was performed, 0.6%
had a value of ≥ 20 µIU/ml. Of these, 77% were reported to the general paediatrician or neonatologist. Critical result
reporting was improved after the audit, and further enhanced the laboratory service of CH screening.
Keywords: Congenital hypothyroidism, Thyroid-stimulating hormones, Newborn screening, Critical results
Introduction
Newborn screening (NBS) programs are considered the
most extensive preventive medicine system and a vital
element of public health. The newborns are tested for
specific disorders, not symptomatically present at the
time of birth, but if remain untreated can permanently
impact the health of the baby. The main goal of NBS programs is to reduce morbidity and mortality and improve
the health outcomes of newborns. Congenital hypothyroidism (CH) is a disorder which if screened for in every
newborn has a high benefit-to-risk ratio, as a cost-effective treatment for it is available, it can lead to mental
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retardation if not identified and treated within first few
weeks of birth.
A key-issue in post-analytical quality is represented by
the effectiveness of communication of laboratory data,
particularly communication of critical test results [1].
The idea of critical values reporting to physicians was
first presented by a pathologist, George D. Lundberg, in
1990. It was felt that communicating abnormally high
or low laboratory results to the treating physicians can
help in initiating treatment promptly in life-threatening
situations. Later, critical values reporting received more
focused attention by regulatory authorities and agencies,
including Clinical Laboratory Improvement Amendments of 1988 (CLIA), the Joint Commission (JC) and
the College of American Pathologists (CAP) [2, 3]. The
JC National Patient Safety Goals of 2005, amended in
2013, included a requirement of regularly evaluating the
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timeliness of communication and appropriate actions
to be taken to improve it. Communicating critical test
results was also included in patient safety solutions of
the World Alliance for Patient Safety and World Health
Organization (WHO) Collaborating Centre for Patient
Safety Solutions updated in 2008 by the WHO’s International Steering Committee [1, 4].
Laboratories are responsible for testing, reporting critical results to health care providers, tracking, and improving the timeliness of reporting [5]. Regulatory authorities
have put forth safe practice recommendations regarding
issues related to defining cutoffs for critical results and
their communication [6]. But there exists no consensus
on the choice of analytes to be included in the list of critical results, and clinical laboratories follow both recommendations of scientific societies and clinician’s opinions
in their institutions [7]. Secondly, there is no consensus
on cutoffs for routine biochemical analytes. Laboratories
have to develop their critical results list, define cutoffs,
do regular audits, update this list and cutoffs according
to recent guidelines. However, for newborn screening;
it is recommended that laboratories must determine
screening cutoffs balancing true and false positives, and
determine whether a particular result must be reported
urgently or not urgently, e.g. in CH screening a probable disease result, e.g. over 20 µIU/ml serum would be
reported urgently, e.g. by phone for recommended action
of the clinical referral or diagnostic testing.
One screening test that is critical, and requires immediate clinical action is thyroid-stimulating hormone (TSH),
performed in neonates for screening and confirmation
of congenital hypothyroidism (CH). Timely reporting of
critical values for TSH leads to early treatment, preventing mental retardation, and is therefore vital to patient
safety [8]. According to the American Academy of Pediatrics (AAP) guidelines, nearly 10% of infants with confirmed CH have TSH values between 20 and 40 mIU/l,
where conversion factor for TSH from mU/l to µIU/ml
is 1. It is advisable that in cases with screening test TSH
concentrations between 20 and 40 µIU/ml, serum-free
thyroxine (FT4) and repeat TSH should be analyzed [8].
The estimated incidence of CH is 1 in 1000–1600 live
births in Pakistan, which is higher than the reported incidence in western countries [9, 10]. Guidelines recommend newborn screening for CH should be performed
between 2 and 4 days of age (48–72 h of birth) by analyzing TSH (generally on dried blood spot samples), and
confirmation is done by performing serum TSH and FT4
[11]. According to AAP and American Thyroid Association (ATA) guidelines for newborn screening and
therapy for CH newborn screening test results must be
communicated rapidly back to the general paediatrician
or neonatologist, who is responsible for the follow-up
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of the newborn, for rapid diagnostic testing and decision making regarding patient management [12]. Prompt
reporting of high TSH to the physician will ensure that
treatment is instituted earlier. So this audit was planned
to evaluate the compliance of reporting of results greater
than the screening cutoffs for serum TSH and develop a
mechanism for short-term follow-up.

Main text
Methods

An audit was conducted at Section of Chemical Pathology, Department of Pathology and Microbiology at Aga
Khan University (AKU). The audit was performed from
January 2015 to December 2016, followed by gap analysis, implementation of corrective/preventive measures,
and re-audit in January 2018 to December 2019. At our
centre, infants are discharged after 48 h, and samples are
taken just before discharge. Serum TSH is analyzed at
an automated analyzer ADVIA Centaur (Siemens Diagnostics, US) using a chemiluminescence immunoassay
technique.
The critical result reporting policy for TSH was defined
in consensus with the clinicians, according to the published guidelines for CH screening and diagnosis by AAP
and ATA. Only one level of TSH, i.e. ≥ 20 µIU/ml, was
taken as the critical limit. The communication of critical results procedure was developed as per standards
defined by the JC and CAP. In the case of inpatients, the
attending physician was notified while for outside referrals, parents/guardian were communicated the critical
results. The goal was that 100 per cent of critical results
should be notified to the concerned person, within 24 h
of result availability. The results reported, the technologist informing and parent/physician informed, date and
time of result reporting, results of TSH, and results read
back by the person briefed were documented. The results
which were not critical were reported as per the routine
laboratory practice.
Data were analyzed by Microsoft Excel 2010. Frequencies of serum TSH tests performed, total critical results
analyzed and communicated, and reasons for non-communication were investigated.
Results

A total of 27,407 neonates were screened for CH by
measurement of TSH over 2 years, from 2015 to 2016.
The Median (Q3 − Q1) age of neonates was 3 days (2–4).
During the audit period, 0.7% (n = 182) of critical results
were obtained. The distribution of results appropriately
reported not reported, and reasons for not reporting are
shown in Table 1.
During the audit period, only 23% (n = 50) and 17%
(n = 31) patients were retested for serum TSH (23%) and
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Table 1 Findings of audit and re-audit on status of critical results reported to General Pediatricians and Neonatologists
Cut off (µIU/ml)

N

Audit (Jan 2015–Dec 2016)
n = 27,407
≥ 20

182

≥ 20

139

Re-Audit (Jan 2018–Dec 2019)
n = 22,985

Results reported/
communicated

Results not reported/communicated

Repeat TSH
n (%)

FT4 done
n (%)

Call not received

Contact
not available

Other reason

113 (62%)

17 (9%)

15 (8%)

37 (20%)

50 (23%)

31 (17%)

107 (77%)

8 (6%)

13 (9.4%)

11(8%)

75 (54%)

60 (43%)

FT4 (17%), respectively (Table 1). After the audit, the
project team met to discuss the findings, identify gaps,
suggest corrective or preventive actions, and devise a
strategy to implement these actions, shown in Table 2.
Re-audit was performed from January 2018 to December 2019 after the implementation of corrective actions.
During re-audit period, 22,985 neonates were tested
for TSH with a median age of 3 days (2–4), and 0.6%
(n = 139) critical results were obtained. The distribution
of results reported, patients retested for TSH and FT4 is
shown in Table 1 which shows improvement in newborns
retested for TSH (54% vs 23%) and FT4 (43% vs 17%)
during re-audit period, compared to the audit period.
Discussion

Timely reporting of critical newborn screening results to
the physicians is crucial for patient + 6 safety and prompt
initiation of, thyroxine treatment to avoid irreversible
mental retardation. In the audit period, 0.7% (n = 182)
patients had critical TSH levels, and only two-thirds of
these were reported appropriately.
Guidelines also recommend repeating TSH and perform FT4 test before initiating CH treatment, so we
also evaluated the number of repeat TSH, and FT4 performed on patients with critical results. In the present
study, only 54% of patients were retested for serum TSH,

and 43% were also tested for serum FT4 during the reaudit period. Although the number of patients retested
was increased compared to the audit period, however, it
was lower than the previously reported audits. An audit
done by Jones JH on the improvements in screening performance of a Scottish newborn screening program for
CH, observed that only 82% of the newborns notified of
high TSH results were resampled for TSH analysis [13].
The reason for this difference could be that patients were
evaluated and tested at another laboratory. Another reason can be that AAP guidelines suggest that every newborn with serum TSH ≥ 40uIU/ml should immediately
be initiated on thyroxine treatment and simultaneously
a repeat sample should be sent for TSH and FT4 analysis for the confirmation of CH. In contrast, only 10% of
the newborns with serum TSH levels between 20 and
40 µIU/ml develop confirmed CH. When using a higher
cutoff, i.e. serum TSH of ≥ 40 µIU/ml for the recall of
patients, physicians will be more inclined towards retesting for both TSH and FT4 (1 µIU/ml = 1 mU/l).
Gap analysis revealed that the most common reason for non-communication of critical results was nonavailability of the contact information or phone calls
not received by physicians or patients’ parents/guardians. A similar survey was done in the Italian population
reporting 7 years’ experience from the screening centre

Table 2 Gaps identified after audit and correct or preventive actions taken
S# Gap identified

Corrective/preventive action taken

1

Unavailability of contacts of mostly outside referral patients

Medical receptionists and personnel entering information in the medical
records were reminded to take patient contact numbers while ordering the
TSH test

2

Technologists lack critical results reporting policy knowledge

A competency assessment of technologists was performed to evaluate knowledge of the critical results reporting policy
Knowledge of the policy was made part of the technologist competency
assessment form for serum TSH analysis

3

Critical results for TSH were not highlighted on a computer display Critical results of TSH were highlighted and in a different colour in the integrated laboratory management system

4

No monitoring of critical results reported

The critical result reported was made a quality indicator with daily monitoring
The goal was set as 100% critical results reported
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in the Lombardy region, Italy. The authors reported that
the main reason for the non-communication of critical
results was the relocation of families and lack of contact information. [14]. Another study from the Hospital for Sick Children in Toronto, Ontario, reported that
potential reasons for non-communication of results
were service-related commitments of staff responsible
for informing and attempting to find ordering physicians
via informal channels [15]. In the present study, the technologist responsible for analysis and communicating or
notifying critical serum TSH results were unable to do
so due to their high workload. Since there was no monitoring system in place, there were delays in reporting the
critical result.
After the re-audit, the audit team gave the following
recommendation:
• Communication pathway: a communication pathway be developed (Fig. 1), as the most common reason for non-communication was the unavailability of
contact information or phone not received. In a new
pathway, all results of inpatients with levels ≥ 20 µIU/
ml should be informed to a pediatric endocrine nurse

•
•
•

•

available at the endocrine hotline. The nurse notifies
these results to the patients’ general paediatrician or
neonatologist, and pediatric endocrinologists. She
also calls and advice the patient to perform confirmatory testing and arranges a follow-up consultation.
For outside referrals, parents are notified of the
results and advised to consult the patients’ general
paediatrician or neonatologist, shown in Fig. 1.
The collecting laboratory should ensure that contact
information is included on all serum TSH request
forms.
Communications are monitored and audited
regularly: the audit team further suggested that
the percentage of subjects notified with serum
TSH ≥ 20 µIU/ml should be made a quality indicator
and regularly monitored, as well as audited periodically.
Interpretative comments on reports: after the reaudit period, only 30–55% of patients were retested
for TSH and FT4. To increase the proportion of
babies receiving repeat testing, a comment can be
added to reports of critical TSH levels recommending to repeat TSH and perform FT4 testing and fol-

Serum TSH performed

Results >20uIU/ml

Outside Referral

Informed to Parents/Guardian.
Advised to consult the
peditrician.

Results <20uIU/ml

In-patient

Reported as per routine
practice

Informed to Endocrine hotline

The Endocrine hotline is maintained by a nurse, who is responsible to:
1. Call parents the same day, inform them of these results & advise them to
follow up with the primary consultant.
2. Text the parents on their cell phone stating the tests which are required to be
done: TSH & FT4.
3. Email the primary consultant and copying both the endocrinologists about
the results along with name and Identification number of the patient.
Fig. 1 Communication pathway for serum TSH critical results reporting
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low up with paediatrician advised for further management. This comment was added in all serum TSH
reports with levels ≥ 20 µIU/ml.
These recommendations put forward by the audit team
were implemented successfully. Although there were
some hitches initially, and the pathway defined was followed rigorously and monitored regularly.
Conclusion

Newborn screening for congenital hypothyroidism is
perceived as a very beneficial publish health program. All
developed countries and many developing countries now
have established newborn screening programs, at least
for CH. Laboratory services for CH newborn screening
can be improved by introducing critical results reporting
of high TSH levels to the concerned physician. The current audit has effectively improved monitoring of postanalytical practices. Timely informing critical results to
the physicians is crucial for patient safety, treatment can
be started on time, and irreversible mental retardation
can be prevented.

Limitations
• The limitations of this audit were that thyroid hormones and antibody status of mothers of the neonates was not known. Newborns babies born to
mothers with thyroidal illnesses can present with
abnormal TSH levels and may be misdiagnosed.
• A single cutoff and not age-related cutoffs were used
for screening, adopted from AAP guidelines. Along
with serum TSH, FT4 was not performed with the
initial sample, and repeat testing results for NTSH of
all patients were not known.
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